Collaboration to Evaluate Combination of OncoSec’s Proprietary Intratumoral DNA Delivery Technology with Heat’s Proprietary Impact Platform to Treat Variety of Cancers
SAN DIEGO, CA & DURHAM, NC, USA I February 18, 2015 I OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, and Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.
Under the agreement, OncoSec and Heat will jointly evaluate the preclinical efficacy of OncoSec’s core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform, with Heat’s proprietary gp-96-Ig based ImPACT immunotherapy platform.
“We are excited to initiate this collaboration with OncoSec, one of the leaders in the field of intratumoral DNA delivery,” said Taylor Schreiber, MD, PhD, Heat’s Vice President of Research and Development. “This collaboration with OncoSec reflects our desire to expand Heat’s ImPACT platform into DNA-based immunotherapies to stimulate immunity to both shared and private tumor antigens without introducing the complexities associated with personalized therapies,” Dr. Schreiber added.
“In this collaboration we will evaluate the efficacy of Heat’s proprietary DNA constructswith OncoSec’s clinical stage electroporation platform,” said Robert H. Pierce, MD, OncoSec’s Chief Scientific Officer. “Heat’s ImPACT platform is a unique approach that specifically activates tumor specific cytotoxic T-cells. We expect it will be effective with OncoSec’s proprietary intratumoral delivery platform that has already shown promising clinical activity in both local and distant tumors in patients with metastatic melanoma,” Dr. Pierce stated.
OncoSec and Heat are exploring this combination as part of their ongoing strategy to expand the application of their technologies to benefit cancer patients with unmet medical needs. OncoSec’s core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, is currently in Phase 2 clinical trials, investigating the approach for treatment of metastatic melanoma, head and neck cancer, triple negative breast cancer, and cutaneous T-cell lymphoma. Heat has two clinical stage programs based on the ImPACT platform, viagenpumatucel-L (HS-110) in a Phase 2 clinical trial in patients with non-small cell lung cancer and vesigenurtacel-L (HS-410) in a Phase 2 clinical trial in patients with non-muscle invasive bladder cancer.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical’s core technology is designed to enhance the local delivery and uptake of plasmid-encoded IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, “off-the-shelf” ImPACTtherapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to “pump out” a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called “gp96” to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.
SOURCE: Heat Biologics
Post Views: 156
Collaboration to Evaluate Combination of OncoSec’s Proprietary Intratumoral DNA Delivery Technology with Heat’s Proprietary Impact Platform to Treat Variety of Cancers
SAN DIEGO, CA & DURHAM, NC, USA I February 18, 2015 I OncoSec Medical Inc. (“OncoSec”) (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, and Heat Biologics, Inc. (“Heat”) (NASDAQ: HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company.
Under the agreement, OncoSec and Heat will jointly evaluate the preclinical efficacy of OncoSec’s core technology, ImmunoPulse, an investigational stage intratumoral DNA delivery platform, with Heat’s proprietary gp-96-Ig based ImPACT immunotherapy platform.
“We are excited to initiate this collaboration with OncoSec, one of the leaders in the field of intratumoral DNA delivery,” said Taylor Schreiber, MD, PhD, Heat’s Vice President of Research and Development. “This collaboration with OncoSec reflects our desire to expand Heat’s ImPACT platform into DNA-based immunotherapies to stimulate immunity to both shared and private tumor antigens without introducing the complexities associated with personalized therapies,” Dr. Schreiber added.
“In this collaboration we will evaluate the efficacy of Heat’s proprietary DNA constructswith OncoSec’s clinical stage electroporation platform,” said Robert H. Pierce, MD, OncoSec’s Chief Scientific Officer. “Heat’s ImPACT platform is a unique approach that specifically activates tumor specific cytotoxic T-cells. We expect it will be effective with OncoSec’s proprietary intratumoral delivery platform that has already shown promising clinical activity in both local and distant tumors in patients with metastatic melanoma,” Dr. Pierce stated.
OncoSec and Heat are exploring this combination as part of their ongoing strategy to expand the application of their technologies to benefit cancer patients with unmet medical needs. OncoSec’s core platform, ImmunoPulse, which is based on the intratumoral delivery of DNA IL-12, is currently in Phase 2 clinical trials, investigating the approach for treatment of metastatic melanoma, head and neck cancer, triple negative breast cancer, and cutaneous T-cell lymphoma. Heat has two clinical stage programs based on the ImPACT platform, viagenpumatucel-L (HS-110) in a Phase 2 clinical trial in patients with non-small cell lung cancer and vesigenurtacel-L (HS-410) in a Phase 2 clinical trial in patients with non-muscle invasive bladder cancer.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its investigational ImmunoPulse intratumoral cancer immunotherapy. OncoSec Medical’s core technology is designed to enhance the local delivery and uptake of plasmid-encoded IL-12 and other DNA-based immune-targeting agents. Clinical studies of ImmunoPulse have demonstrated an acceptable safety profile and preliminary evidence of anti-tumor activity in the treatment of various skin cancers, as well as the potential to initiate a systemic immune response without the systemic toxicities associated with other treatments. OncoSec’s lead program evaluating ImmunoPulse for the treatment of metastatic melanoma is currently in Phase 2 development, and is being conducted in collaboration with several prominent academic medical centers. As the company continues to evaluate ImmunoPulse in its current indications, it is also focused on identifying and developing new immune-targeting agents, investigating additional tumor indications, and evaluating combination-based immunotherapy approaches. For more information, please visit www.oncosec.com.
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, “off-the-shelf” ImPACTtherapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to “pump out” a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called “gp96” to educate and activate a cancer patient’s immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.
SOURCE: Heat Biologics
Post Views: 156
